Concurrent FDA approval and the establishment of Medicare coverage will propel Next generation sequencing squarely into the mainstream of oncology practice, said Vincent Miller, chief medical officer of Foundation Medicine Inc.
In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology.
